Approved for ACBS conditions, e.g. dry mouth (xerostomia) as a result of having (or having undergone) radiotherapy, or sicca syndrome. Palliative Care, dental practitioners.

Prescribe by brand to ensure patients receive the device they are used to. Check licensed indication (differences among brands). Be aware of differences in excipients among the different brands- APC listing of current formulary brands

For Wolman disease

For patients with swallowing difficulties only

The use of semaglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place.

Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes.

The Wegovy® brand of semaglutide is not commercially available yet.

Specialist recommendation.

Hospital use only. NHS England commissioned.

Hospital use only. NHS England commissioned.

Sildenafil tablets generic

MHRA advice regarding high dose simvastatin (May 2010):
• Simvastatin 80 mg should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who have not
achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks
• Prescribers treating patients who are taking simvastatin 80 mg or who are being considered for an up-titration to that dose may need to review their
treatment during their next visit, to take into account the new evidence
• Patients who are currently taking simvastatin 80 mg should not stop taking their medicine. However, they should be advised to contact their doctor
immediately if they experience unexplained muscle pain, tenderness, or weakness
• Please report suspected adverse reactions with medicines, including statins, to us via the Yellow Card Scheme (www.yellowcard.gov.uk)